These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27378343)

  • 1. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.
    St John LS; Wan L; He H; Garber HR; Clise-Dwyer K; Alatrash G; Rezvani K; Shpall EJ; Bollard CM; Ma Q; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):995-1001. PubMed ID: 27378343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
    Molldrem JJ; Lee PP; Wang C; Champlin RE; Davis MM
    Cancer Res; 1999 Jun; 59(11):2675-81. PubMed ID: 10363991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
    Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
    Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.
    Ma Q; Wang C; Jones D; Quintanilla KE; Li D; Wang Y; Wieder ED; Clise-Dwyer K; Alatrash G; Mj Y; Munsell MF; Lu S; Qazilbash MH; Molldrem JJ
    Cytotherapy; 2010 Dec; 12(8):1056-62. PubMed ID: 20735170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase.
    Fujiwara H; El Ouriaghli F; Grube M; Price DA; Rezvani K; Gostick E; Sconocchia G; Melenhorst J; Hensel N; Douek DC; Barrett AJ
    Blood; 2004 Apr; 103(8):3076-83. PubMed ID: 15070688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.
    Molldrem JJ; Clave E; Jiang YZ; Mavroudis D; Raptis A; Hensel N; Agarwala V; Barrett AJ
    Blood; 1997 Oct; 90(7):2529-34. PubMed ID: 9326217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
    Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
    J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.
    Molldrem J; Dermime S; Parker K; Jiang YZ; Mavroudis D; Hensel N; Fukushima P; Barrett AJ
    Blood; 1996 Oct; 88(7):2450-7. PubMed ID: 8839835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo specific induction of CD8 positive anti-leukemia cytotoxic lymphocytes from umbilical cord blood.
    Tan H; Liu X; Ye X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):129-33. PubMed ID: 17490538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.
    Alatrash G; Mittendorf EA; Sergeeva A; Sukhumalchandra P; Qiao N; Zhang M; St John LS; Ruisaard K; Haugen CE; Al-Atrache Z; Jakher H; Philips AV; Ding X; Chen JQ; Wu Y; Patenia RS; Bernatchez C; Vence LM; Radvanyi LG; Hwu P; Clise-Dwyer K; Ma Q; Lu S; Molldrem JJ
    J Immunol; 2012 Dec; 189(11):5476-84. PubMed ID: 23105141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
    Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
    Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.
    Weber G; Gerdemann U; Caruana I; Savoldo B; Hensel NF; Rabin KR; Shpall EJ; Melenhorst JJ; Leen AM; Barrett AJ; Bollard CM
    Leukemia; 2013 Jul; 27(7):1538-47. PubMed ID: 23528871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation.
    Mutis T; Blokland E; Kester M; Schrama E; Goulmy E
    Blood; 2002 Jul; 100(2):547-52. PubMed ID: 12091347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
    Bae J; Martinson JA; Klingemann HG
    Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
    Bae J; Martinson JA; Klingemann HG
    Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.
    Lacey SF; La Rosa C; Kaltcheva T; Srivastava T; Seidel A; Zhou W; Rawal R; Hagen K; Krishnan A; Longmate J; Andersson HA; St John L; Bhatia R; Pullarkat V; Forman SJ; Cooper LJ; Molldrem J; Diamond DJ
    Blood; 2011 Aug; 118(8):2159-69. PubMed ID: 21719601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation.
    Robinson KL; Ayello J; Hughes R; van de Ven C; Issitt L; Kurtzberg J; Cairo MS
    Exp Hematol; 2002 Mar; 30(3):245-51. PubMed ID: 11882362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
    Herrmann AC; Im JS; Pareek S; Ruiz-Vasquez W; Lu S; Sergeeva A; Mehrens J; He H; Alatrash G; Sukhumalchandra P; St John L; Clise-Dwyer K; Zha D; Molldrem JJ
    Front Immunol; 2018; 9():3153. PubMed ID: 30713535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
    Qazilbash MH; Wieder E; Thall PF; Wang X; Rios R; Lu S; Kanodia S; Ruisaard KE; Giralt SA; Estey EH; Cortes J; Komanduri KV; Clise-Dwyer K; Alatrash G; Ma Q; Champlin RE; Molldrem JJ
    Leukemia; 2017 Mar; 31(3):697-704. PubMed ID: 27654852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.